List of Afinitor Disperz drug patents

Afinitor Disperz is owned by Novartis Pharm.

Afinitor Disperz contains Everolimus.

Afinitor Disperz has a total of 4 drug patents out of which 3 drug patents have expired.

Expired drug patents of Afinitor Disperz are:

  • US8778962
  • US8778962*PED
  • US8617598

Afinitor Disperz was authorised for market use on 29 August, 2012.

Afinitor Disperz is available in tablet, for suspension;oral dosage forms.

Afinitor Disperz can be used as treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; adjunctive treatment of patients with tsc-associated partial-onset seizures.

The generics of Afinitor Disperz are possible to be released after 10 April, 2025.

Can you believe AFINITOR DISPERZ received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778962 NOVARTIS PHARM Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(11 months ago)

US8778962

(Pediatric)

NOVARTIS PHARM Treatment of solid tumors with rapamycin derivatives
Aug, 2022

(5 months ago)

US8617598 NOVARTIS PHARM Pharmaceutical compositions comprising colloidal silicon dioxide
Sep, 2022

(4 months ago)

US8617598

(Pediatric)

NOVARTIS PHARM Pharmaceutical compositions comprising colloidal silicon dioxide
Mar, 2023

(a month from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 10, 2025

Drugs and Companies using EVEROLIMUS ingredient

Market Authorisation Date: 29 August, 2012

Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Adjunctive treatment of patients with tsc-associated partial-onset seizures

Dosage: TABLET, FOR SUSPENSION;ORAL

How can I launch a generic of AFINITOR DISPERZ before it's patent expiration?
More Information on Dosage

AFINITOR DISPERZ family patents

16

Japan

15

Norway

15

European Union

14

United States

11

Israel

10

Spain

10

China

9

Hong Kong

9

Lithuania

9

Portugal

9

Russia

8

Cyprus

8

Denmark

7

Slovenia

6

Poland

5

Slovakia

5

Czech Republic

4

Korea, Republic of

4

Mexico

4

Canada

3

Brazil

3

Luxembourg

3

United Kingdom

3

New Zealand

3

Taiwan, Province of China

2

Hungary

2

Argentina

2

South Africa

1

Austria

1

Australia

1

Malaysia

1

Germany

1

Colombia

1

Peru

1

Ecuador

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in